Karyopharm Therapeutics (NASDAQ:KPTI) jumps 42% premarket on increased volume in reaction to positive results from a Phase 3 clinical trial, BOSTON, evaluating the combination of Xpovio (selinexor), Takeda’s (NYSE:TAK)
Velcade (bortezomib) and low-dose dexamethasone in multiple myeloma
patients who had received one-to-three prior lines of treatment.
The study met the primary endpoint of a
statistically significant improvement in progression-free survival (PFS)
compared to Velcade + dexamethasone (Vd). Specifically, median PFS in
the triplet arm was 13.93 months versus 9.46 months in the Vd arm
(p=0.007) with 30% less risk of disease progression (hazard ratio =
0.70).
Compete data will be submitted for presentation at future medical conferences.
https://seekingalpha.com/news/3547371-karyopharm-up-45-premarket-on-positive-selinexor-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.